Access to MINDACT data and residual material

Intro text: 

- 8 January 2018 -

The main results of the MINDACT trial (BIG 3-04) were published in the New England Journal of Medicine in 2016, and the findings of the chemotherapy randomisation were presented last June at ASCO Annual Meeting.

Applications for access to data and residual biological material from MINDACT may be submitted throughout the year. More information and the application form can be found on .

If you have any questions about the use of MINDACT data or residual biological material, please contact the study team at EORTC:

MINDACT is a prospective, randomised study designed to evaluate the utility of adding the 70-gene test (Mammaprint®) to the traditional method of assessing the likelihood of breast cancer recurrence for women with node-negative or 1-to-3 node positive breast cancer ( identifier: NCT00433589). The study is sponsored and run by the EORTC, in collaboration with BIG.

Read more about MINDACT